What Is Amastatin? Definition and What Research Reports
Amastatin is a small, naturally occurring peptide compound, originally isolated from Streptomyces culture broths, that is described in the literature as an inhibitor of certain aminopeptidases. It is not a therapeutic product; in published work it appears almost entirely as a laboratory reagent used to slow the breakdown of peptides by N-terminal-cleaving enzymes. Studies citing this class of inhibitor span enzyme characterisation in invertebrates, receptor pharmacology with peptide agonists, and neuropeptide experiments in rodents. This page is definitional and summarises reported findings only.
Definition
Amastatin is a small, naturally occurring peptide compound that is described in the biochemical literature as an inhibitor of certain aminopeptidases — the enzymes that trim amino acids from the free N-terminus of peptides and proteins. It was originally isolated from Streptomyces culture broths, and its structure is usually written as an unusual hydroxy-amino acid residue, (2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl, joined to a short chain of valine, valine and aspartic acid. In practice the word "amastatin" is used in two ways: as the name of that specific molecule, and as shorthand for the broader category of peptide-based aminopeptidase inhibitors that researchers add to buffers, tissue baths and cell media so that a peptide of interest survives long enough to be measured. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or medication.
What Class of Molecule Is It, and Where Does It Come From?
Amastatin belongs to the family of microbial peptide metabolites — compounds produced by soil bacteria that happen to bind tightly to the active site of a mammalian or invertebrate enzyme. Structurally it sits alongside bestatin and other "statin"-type inhibitors whose defining feature is a modified amino acid that mimics the transition state of peptide bond cleavage. That mimicry is why the molecule is classed as a competitive, reversible enzyme inhibitor rather than a receptor ligand, a hormone analogue or a signalling peptide. It is a reagent-grade research chemical, not an approved medicine, and it does not appear in any regulatory approval as a therapeutic ingredient.
Where the term shows up
- Enzymology: in papers that classify aminopeptidase families (M1, M17, M18 and related clans) by how they respond to inhibitor panels.
- Receptor pharmacology: in methods sections, where a peptide agonist with a free N-terminus would otherwise be degraded before it reaches its receptor.
- Neuropeptide research: in rodent studies of peptides such as dynorphin, oxytocin and the angiotensins, where N-terminal trimming changes which fragment is present.
What the Published Literature Reports
The verified papers below do not describe amastatin as a treatment. They describe the enzymes and peptide systems that make aminopeptidase inhibition a routine experimental step, and what researchers observed in those systems.
Aminopeptidase characterisation
A 2002 helminthology study detected aminopeptidase activity in Caenorhabditis elegans and Panagrellus redivivus using both peptide and non-peptide substrates, and the study reported that substrate profiling could distinguish enzyme activities between the two nematode species (PMID 12018195). A 2020 survey of marine invertebrates collected from the Cuban coastline reported biochemical evidence for M1-, M17- and M18-like aminopeptidases across the sampled organisms, with the enzyme families assigned on the basis of substrate and inhibitor behaviour (PMID 32609656). Work on inhibitors of the same enzyme target has continued: a 2019 study reported that pentapeptide microginins inhibited porcine aminopeptidase M, a mammalian M1-family enzyme of the kind amastatin is also described as acting on (PMID 31795383).
Peptide metabolism in tissue and cell systems
Because aminopeptidases determine how long a peptide survives, several studies have mapped inactivation pathways directly. Researchers using isolated human umbilical vein reported functional evidence for an enzymatic inactivating pathway for des-Arg10-kallidin, identifying the peptidase steps that terminate the kinin response in that preparation (PMID 17372720). In the renin–angiotensin system, N-terminal trimming is not merely degradation but conversion: a 2013 study reported distinct molecular effects of angiotensin II and angiotensin III in cultured rat astrocytes, underlining why experiments must control which of the two fragments is present (PMID 23476748). A 2014 neuroendocrinology study described oxytocinase activity in the female rat hypothalamus and reported it as a mechanism controlling oxytocin neurones during lactation (PMID 24612105).
Receptor studies with N-terminal peptide agonists
Protease-activated receptors are activated by short peptides whose free N-terminus is essential, so aminopeptidase control is a standard part of the method. A 2002 study of proteinase-activated receptor agonists in human platelets reported the mechanisms by which those agonists produced platelet responses (PMID 11877318). Another 2002 report localised protease-activated receptor-2 in the pancreas and parotid gland and reported the involvement of nitric oxide in evoked amylase secretion (PMID 12231404). In rat gastric mucosa, researchers reported a protective role for protease-activated receptor 1 (PMID 14699501).
Peptidase inhibitors in rodent neuropeptide work
One rat study is directly about the inhibitor category itself: researchers administered dynorphin A (1-17) or dynorphin A (1-13) intracerebroventricularly together with three peptidase inhibitors and reported effects on both antinociceptive potential and toxicity (PMID 24943455). That combination of endpoints — activity and toxicity measured together — is the closest the verified literature comes to characterising what happens when peptidase inhibition is applied in vivo, and it was conducted in rats rather than humans.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow the Term Is Used: A Quick Map
| Context | What the cited study examined | Reference |
|---|---|---|
| Invertebrate enzymology | Aminopeptidase detection in two nematode species | PMID 12018195 |
| Marine biochemistry | M1-, M17- and M18-like aminopeptidases in invertebrates | PMID 32609656 |
| Inhibitor chemistry | Microginin inhibition of porcine aminopeptidase M | PMID 31795383 |
| Peptide inactivation | Des-Arg10-kallidin inactivation in human umbilical vein | PMID 17372720 |
| Neuropeptide processing | Hypothalamic oxytocinase during lactation in rats | PMID 24612105 |
| Fragment-specific signalling | Angiotensin II versus angiotensin III in rat astrocytes | PMID 23476748 |
Adverse Events: What Studies Report
The verified literature contains no human safety or tolerability trial of amastatin, and no approved product contains it. The single in vivo report that pairs a peptidase-inhibitor manipulation with a safety endpoint is the rat dynorphin study, in which researchers reported both antinociceptive potential and toxicity after intracerebroventricular administration (PMID 24943455). Separately, a cultured normal human epidermal keratinocyte model examined sulfur mustard-stimulated proteases and their inhibitors, and the study framed protease inhibition as a potential approach for anti-vesicant drug development rather than as an established intervention (PMID 28959561). Nothing in these reports describes safe or unsafe use in people, and none of the material on this page should be read as guidance.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated Terms
- Aminopeptidase: an enzyme that removes amino acids from the N-terminus of a peptide.
- Aminopeptidase A / M1 family: enzyme groups repeatedly assayed in the studies cited above (PMID 32609656).
- Oxytocinase: a placental/hypothalamic aminopeptidase reported as regulating oxytocin neurones in lactating rats (PMID 24612105).
- Research-use-only (RUO): the regulatory label typically applied to laboratory reagents of this kind.
References
- Aminopeptidases in Caenorhabditis elegans and Panagrellus redivivus: detection using peptide and non-peptide substrates (Journal of Helminthology, 2002)
- Biochemical evidences for M1-, M17- and M18-like aminopeptidases in marine invertebrates from Cuban coastline (Zeitschrift fur Naturforschung C, 2020)
- Inhibition of Porcine Aminopeptidase M (pAMP) by the Pentapeptide Microginins (Molecules, 2019)
- Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein (Naunyn-Schmiedeberg's Archives of Pharmacology, 2007)
- Distinct Molecular Effects of Angiotensin II and Angiotensin III in Rat Astrocytes (International Journal of Hypertension, 2013)
- Oxytocinase in the female rat hypothalamus: a novel mechanism controlling oxytocin neurones during lactation (Journal of Neuroendocrinology, 2014)
- Mechanisms of action of proteinase-activated receptor agonists on human platelets (British Journal of Pharmacology, 2002)
- Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: Immunolocalization and involvement of nitric oxide in the evoked amylase secretion (Life Sciences, 2002)
- A protective role of protease-activated receptor 1 in rat gastric mucosa (Gastroenterology, 2004)
- Effect of three peptidase inhibitors on antinociceptive potential and toxicity with intracerebroventricular administration of dynorphin A (1-17) or (1-13) in the rat (Journal of Anesthesia, 2015)
- Sulfur mustard-stimulated proteases and their inhibitors in a cultured normal human epidermal keratinocytes model (Toxicology Reports, 2016)
Frequently asked questions
What is amastatin, in one sentence?▾
Amastatin is a small, naturally occurring peptide compound described in the biochemical literature as an inhibitor of certain aminopeptidases — enzymes that clip amino acids from the N-terminus of peptides. It is used as a laboratory reagent rather than as a therapeutic product, and it appears in studies that characterise aminopeptidase families such as those surveyed in marine invertebrates (PMID 32609656).
Where does amastatin come from?▾
It is a microbial metabolite, originally isolated from Streptomyces culture broths, which places it in the same broad group as other bacteria-derived peptide enzyme inhibitors. Related inhibitor chemistry is still actively studied: a 2019 report described pentapeptide microginins inhibiting porcine aminopeptidase M, an enzyme of the same M1 family that amastatin is commonly described as targeting (PMID 31795383).
Why do researchers add aminopeptidase inhibitors to experiments?▾
Because many signalling peptides are inactivated — or converted into a different active fragment — by N-terminal trimming. Researchers reported that angiotensin II and angiotensin III produced distinct molecular effects in rat astrocytes, which shows why controlling that conversion matters (PMID 23476748). Similar logic applies to kinin inactivation studied in isolated human umbilical vein (PMID 17372720).
Is amastatin a medicine or an approved drug?▾
No. Nothing in the published literature summarised here describes amastatin as an approved therapeutic, and it is generally handled as a research-use-only laboratory chemical. Related protease-inhibition strategies have been framed as early research directions rather than established treatments — for example, in a cultured human keratinocyte model of sulfur mustard injury (PMID 28959561).
What has been reported in animals about peptidase inhibition?▾
One rat study administered dynorphin A (1-17) or dynorphin A (1-13) intracerebroventricularly along with three peptidase inhibitors, and researchers reported on both antinociceptive potential and toxicity in that model (PMID 24943455). Those were animal findings under controlled laboratory conditions, and the study did not establish anything about use in people.
How does amastatin relate to protease-activated receptor research?▾
Protease-activated receptors are triggered by short peptides whose free N-terminus is essential, so aminopeptidase control is a common methodological concern. Studies in this area reported mechanisms of proteinase-activated receptor agonists in human platelets (PMID 11877318), PAR-2 localisation with nitric oxide involvement in amylase secretion (PMID 12231404), and a protective role for PAR-1 in rat gastric mucosa (PMID 14699501).
Does amastatin affect neuropeptides such as oxytocin?▾
The relevant enzyme, oxytocinase, is an aminopeptidase. A 2014 study described oxytocinase in the female rat hypothalamus and reported it as a mechanism controlling oxytocin neurones during lactation (PMID 24612105). That work characterises the enzyme system itself; it does not describe amastatin as a treatment, and this page is educational only, not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.